Log in to your Inderes Free account to see all free content on this page.
Infant Bacterial Therapeutics
56.00 SEK
+0.90 %
Less than 1K followers
IBT B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+0.90 %
+12.34 %
+19.40 %
+10.89 %
-5.72 %
-1.75 %
+12.00 %
-40.30 %
-4.21 %
Infant Bacterial Therapeutics is a biotechnology company focused on developing innovative treatments for inflammatory bowel diseases. The company develops, among other things, medicines to treat and prevent common conditions and diseases in children that occur at early birth. The business is global with a primary presence in Europe and North America. Infant Bacterial Therapeutics was founded in 2011 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
754.4M SEK
Turnover
281.31K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
6.5.
2026
Interim report Q1'26
7.5.
2026
General meeting '26
26.8.
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Notice of Annual General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB publishes the Annual Report for 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio